Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2022

Open Access 01-12-2022 | Metastasis | Research

Establishment of an optimized orthotopic bladder cancer model in mice

Authors: Jinming Cai, Zhiwen Xie, Yilin Yan, Zhengnan Huang, Pengfei Tang, Xiangqian Cao, Zeyi Wang, Chenkai Yang, Mingyue Tan, Fang Zhang, Bing Shen

Published in: BMC Urology | Issue 1/2022

Login to get access

Abstract

Background

Bladder cancer (BC) is one of the most common malignancies of the genitourinary system. Animal models offer an important tool to explore tumour initiation, progression, and therapeutic mechanisms. Our aim is to construct an optimized orthotopic BC model which is predictable, reproducible, and convenient.

Methods

The optimized orthotopic BC model was constructed in male C57BL/6 mice utilizing microsyringes to inoculate them with a murine BC cell line (MB49). Anesthetised mice were inoculated with an MB49 cell suspension (10 µL) at approximately 5 × 106/mL. The whole process of modelling was observed and monitored every 3 days for 21 days utilizing HE staining and transabdominal ultrasonography (TUS).

Results

In this study, the model showed excellent success rates for tumour formation (96.67%) and metastatic rate (89.66%). Compared to the control group (sham operation), mice in the modelling group had serous cachexia, visible haematuresis and weight loss (all P < 0.05). The lungs, liver, ureter and kidneys were found to have tumour metastasis. Moreover, the average survival time (19.73 ± 1.69 d) of modelling mice was significantly shorter than that of the control mice (P < 0.05), which remained alive.

Conclusion

Our study established a method using microsyringes to inject murine BC cells into the bladder wall, creating a stable transplantable BC model in mice.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.PubMedCrossRef
3.
Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020;6(4):653–63.PubMedCrossRef
4.
5.
Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75.PubMedCrossRef
6.
Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.PubMedCrossRef
7.
Ratliff TL. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin. Clin Infect Dis. 2000;31(Suppl 3):S106–8.PubMedCrossRef
8.
Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 1999;81(4):638–46.PubMedPubMedCentralCrossRef
9.
Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 1979;62(4):1017–23.PubMed
10.
Chen Z, Tao Z-Z, Chen S-M, Chen C, Li F, Xiao B-K. Indole-3-carbinol inhibits nasopharyngeal carcinoma growth through cell cycle arrest in vivo and in vitro. PLoS ONE. 2013;8(12):e82288.PubMedPubMedCentralCrossRef
11.
Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009;104(9):1286–91.PubMedCrossRef
12.
Chade DC, Andrade PM, Borra RC, Leite KR, Andrade E, Villanova FE, et al. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol. 2008;34(2):220–9.PubMedCrossRef
13.
Lodillinsky C, Rodriguez V, Vauthay L, Sandes E, Casabé A, Eiján AM. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol. 2009;182(2):749–55.PubMedCrossRef
14.
Reis LO, Ferreira U, Billis A, Cagnon VHA, Fávaro WJ. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 2012;187(2):438–45.PubMedCrossRef
15.
Miyazaki J, Nishiyama H, Yano I, Nakaya A, Kohama H, Kawai K, et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res. 2011;31(6):2065–71.PubMed
16.
Shen Z-J, Wang Y, Ding G-Q, Pan C-W, Zheng R-M. Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol. 2007;25(5):525–9.PubMedCrossRef
17.
Black PC, Dinney CPN. Bladder cancer angiogenesis and metastasis–translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26(3–4):623–34.PubMedCrossRef
18.
Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, Mennel HD, Stahl KW. Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-nitrosamine. Z Krebsforsch. 1964;66:280–90.PubMedCrossRef
19.
Fukushima S, Hirose M, Tsuda H, Shirai T, Hirao K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gan. 1976;67(1):81–90.PubMed
20.
Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (New York, NY). 2008;10(8):838–46.CrossRef
21.
Lin JH, Zhao H, Sun TT. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA. 1995;92(3):679–83.PubMedPubMedCentralCrossRef
22.
Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2(12):1008–14.PubMedCentralCrossRef
23.
Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, et al. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS ONE. 2013;8(9): e74809.PubMedPubMedCentralCrossRef
24.
Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15(1):42–54.PubMedPubMedCentralCrossRef
25.
Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J Urol. 2012;187(3):1071–9.PubMedCrossRef
26.
Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 1995;154(4):1532–8.PubMedCrossRef
27.
Soloway MS. Intravesical and systemic chemotherapy of murine bladder cancer. Can Res. 1977;37(8 Pt 2):2918–29.
28.
Chin J, Kadhim S, Garcia B, Kim YS, Karlik S. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol. 1991;145(6):1297–301.PubMedCrossRef
29.
Oshinsky GS, Chen Y, Jarrett T, Anderson AE, Weiss GH. A model of bladder tumor xenografts in the nude rat. J Urol. 1995;154(5):1925–9.PubMedCrossRef
30.
Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LCC, Andrade E, et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res. 2008;27:78.PubMedPubMedCentralCrossRef
31.
Chan ESY, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol. 2009;182(6):2926–31.PubMedCrossRef
32.
Bisson J-F, Parache RM, Droulle P, Notter D, Vigneron C, Guillemin F. A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer. 2002;102(3):280–5.PubMedCrossRef
33.
Jiang F, Zhou XM. A model of orthotopic murine bladder (MBT-2) tumor implants. Urol Res. 1997;25(3):179–82.PubMedCrossRef
34.
Bachor R, Flotte TJ, Scholz M, Dretler S, Hasan T. Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. J Urol. 1992;147(5):1404–10.PubMedCrossRef
35.
Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol. 1991;145(2):279–83.PubMedCrossRef
36.
Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, Elhilali M. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Can Res. 1983;43(2):617–22.
37.
Bonney WW, Henstorf JE, Emaus SP, Lubaroff DM, Feldbush TL. Immunostimulation by cryosurgery: an orthotopic model of prostate and bladder cancer in the rat. Natl Cancer Inst Monogr. 1978;49:375–81.
38.
Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, Tian Z, Becker A, Kluth L, Roos FC, et al. Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer. 2021;19(1):60–8.PubMedCrossRef
39.
Erman A, Kamenšek U, Dragin Jerman U, Pavlin M, Čemažar M, Veranič P, et al. How cancer cells invade bladder epithelium and form tumors: the mouse bladder tumor model as a model of tumor recurrence in patients. Int J Mol Sci. 2021;22(12):6328.PubMedPubMedCentralCrossRef
40.
Morillon YM, Su Z, Schlom J, Greiner JW. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. J Immunother Cancer. 2019;7(1):150.PubMedPubMedCentralCrossRef
41.
Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras AS, et al. Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer. Am J Cancer Res. 2020;10(8):2523–34.PubMedPubMedCentral
42.
Bernardo C, Monteiro FL, Direito I, Amado F, Afreixo V, Santos LL, et al. Association between estrogen receptors and GATA3 in bladder cancer: a systematic review and meta-analysis of their clinicopathological significance. Front Endocrinol (Lausanne). 2021;12: 684140.PubMedCentralCrossRef
43.
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–10.PubMedCrossRef
44.
Bilski K, Dobruch J, Kozikowski M, Skrzypczyk MA, Oszczudłowski M, Ostrowski J. Urobiome in gender-related diversities of bladder cancer. Int J Mol Sci. 2020;21(12):4488.PubMedCentralCrossRef
45.
Martínez-Rojo E, Berumen LC, García-Alcocer G, Escobar-Cabrera J. The role of androgens and androgen receptor in human bladder cancer. Biomolecules. 2021;11(4):594.PubMedPubMedCentralCrossRef
46.
Sottnik JL, Vanderlinden L, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, et al. Androgen receptor regulates CD44 expression in bladder cancer. Can Res. 2021;81(11):2833–46.CrossRef
47.
Wang S, Cai J, Zhang S, Dong M, Zhang L, Xu Y, et al. Loss of polarity protein Par3, via transcription factor snail, promotes bladder cancer metastasis. Cancer Sci. 2021;112(7):2625–41.PubMedPubMedCentralCrossRef
Metadata
Title
Establishment of an optimized orthotopic bladder cancer model in mice
Authors
Jinming Cai
Zhiwen Xie
Yilin Yan
Zhengnan Huang
Pengfei Tang
Xiangqian Cao
Zeyi Wang
Chenkai Yang
Mingyue Tan
Fang Zhang
Bing Shen
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Urology / Issue 1/2022
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-022-01093-6

Other articles of this Issue 1/2022

BMC Urology 1/2022 Go to the issue

Research

Diagnostic dilemmas: a multi-institutional retrospective analysis of adrenal incidentaloma pathology based on radiographic size

Research

CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration

Research

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia

Research

A new nomogram of urinary flow rate and volume based on multiple measurements per healthy adult Japanese men using a portable uroflowmeter (P-Flowdiary®)

Case report

A case report of acute testicular pain secondary to segmental testicular infarction

Research

Effect of AKT silence on malignant biological behavior of renal cell carcinoma cells